The mitochondrial Ca\(^{2+}\) uniporter MCU is required for normal glucose-stimulated insulin secretion \textit{in vitro} and \textit{in vivo}

Elizabeth Haythorne\(^{1†}\), Eleni Georgiadou\(^{1†}\), Matthew T. Dickerson\(^{2}\), Livia Lopez-Noriega\(^{1}\), Timothy J. Pullen\(^{1}\), Gabriela da Silva Xavier\(^{1}\), Samuel P.X. Davis\(^{4}\), Aida Martinez-Sanchez\(^{1}\), Francesca Semplici\(^{1}\), Rosario Rizzuto\(^{3}\), James A. McGinty\(^{4}\), Paul M. French\(^{4}\), Matthew C. Cane\(^{1}\), David A. Jacobson\(^{2}\), Isabelle Leclerc\(^{1}\) and Guy A. Rutter\(^{1*}\)

\(^{1}\)Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, London W12 0NN, UK

\(^{2}\)Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN 37232, USA

\(^{3}\)Department of Biomedical Sciences, University of Padova, Padua, Italy

\(^{4}\)Photonics Group, Department of Physics, Imperial College London, London, SW7 2AZ, UK

Word count: 3920

\(^{†}\)Equal contributions

\(^{*}\)Address correspondence to Professor Guy A. Rutter, g.rutter@imperial.ac.uk and +44 20 7934 3340
Abstract

Mitochondrial oxidative metabolism is central to glucose-stimulated insulin secretion (GSIS). Whether Ca\(^{2+}\) uptake into pancreatic β-cell mitochondria potentiates or antagonises this process is still a matter of debate. Although the mitochondrial importer (MCU) complex is thought to represent the main route for Ca\(^{2+}\) transport across the inner mitochondrial membrane, its role in β-cells has not previously been examined \textit{in vivo}. Here, we inactivated the pore-forming subunit MCUa (MCU) selectively in the β-cell in mice using \textit{Ins1}Cre-mediated recombination. Glucose-stimulated mitochondrial Ca\(^{2+}\) accumulation, ATP production and insulin secretion were strongly (p<0.05 and p<0.01) inhibited in \textit{MCU} null animals (βMCU-KO) \textit{in vitro}. Interestingly, cytosolic Ca\(^{2+}\) concentrations increased (p<0.001) whereas mitochondrial membrane depolarisation improved in βMCU-KO animals. Male βMCU-KO mice displayed impaired \textit{in vivo} insulin secretion at 5 (p<0.001) but not 15 min. post intraperitoneal (IP) injection of glucose while the opposite phenomenon was observed following an oral gavage at 5 min. Unexpectedly, glucose tolerance was improved (p<0.05) in young βMCU-KO (<12 weeks), but not older animals. We conclude that MCU is crucial for mitochondrial Ca\(^{2+}\) uptake in pancreatic β-cells and is required for normal GSIS. The apparent compensatory mechanisms which maintain glucose tolerance in βMCU-KO mice remain to be established.
Introduction

Defective insulin secretion underlies diabetes mellitus, a disease affecting almost 1 in 8 of the adult population worldwide (https://www.idf.org/). The most prevalent form of this condition is Type 2 diabetes (T2D) where pancreatic β-cell failure usually, though not always, occurs in the face of insulin resistance in other tissues (1). Current therapeutic strategies have limited efficacy and there remains a desperate need to develop more effective treatments to tackle this growing epidemic.

Pancreatic β-cells ensure blood glucose homeostasis by responding to a rise in circulating nutrient levels with insulin secretion. Glucose-induced increases in mitochondrial oxidative metabolism are central to the stimulation of insulin secretion, and drive an increase in cytosolic ATP:ADP ratio, closure of ATP-sensitive K⁺ (K\textsubscript{ATP}) channels, Ca\textsuperscript{2+} influx and exocytosis (2). Ca\textsuperscript{2+} ions are also taken up by mitochondria (3; 4) and this has been suggested to activate tricarboxylate (TCA) cycle and other intra-mitochondrial enzymes (5) in order to enhance the production of reducing equivalents for the electron transport chain and ATP generation (2). Although a number of approaches have been used previously to explore the role of intra-mitochondrial Ca\textsuperscript{2+} in controlling insulin secretion, the role of these ions in modifying ATP synthesis, and hence exocytosis, in these cells is still debated (6; 7).

Importantly, there is accumulating evidence to suggest that mitochondrial dysfunction in the pancreatic β-cell leads to impaired glucose-stimulated insulin secretion and may contribute to the development of T2D (8). Moreover, glucolipotoxicity impairs mitochondrial Ca\textsuperscript{2+} uptake in isolated β-cells (9), suggesting a possible role in defective secretion under these conditions.

The mitochondrial Ca\textsuperscript{2+} uniporter (MCU) forms the Ca\textsuperscript{2+}-selective pore of a multiprotein MCU-complex including MCUa [MCU], MICU1-3, MICUR1, and EMRE which allows Ca\textsuperscript{2+} entry.
into mitochondria (10). In vitro and in vivo models of MCU silencing or ablation have revealed a robust reduction in mitochondrial Ca\(^{2+}\) uptake associated with blunted Ca\(^{2+}\)-dependent activation of the TCA cycle, oxygen consumption, ATP production (9; 11; 12) and mitochondrial reactive oxygen species generation (13). Whole body Mcu knockout (KO) mice display normal basal cardiac parameters even though mitochondria isolated from cardiac myocytes display impaired Ca\(^{2+}\) uptake and Ca\(^{2+}\)-dependent oxygen consumption. Interestingly, resting ATP levels are unaltered in muscle cells in Mcu-KO mice, suggesting that MCU depletion does not affect basal mitochondrial metabolism. Mcu-KO mice similarly display only reduced maximal muscle power in association with reduced metabolic flux and activity of TCA cycle enzymes in skeletal muscle mitochondria (11). Given that both cardiac and skeletal muscles are highly metabolically active tissues, it is surprising that whole body Mcu-KO mice display a mild phenotype (11-13). However, glucose homeostasis and insulin secretion were not examined in detail in these earlier studies.

We have previously shown that reducing glucose-stimulated mitochondrial Ca\(^{2+}\) uptake in rodent pancreatic β-cells through knockdown of MCU in vitro impairs the sustained increase in ATP:ADP ratio usually seen in response to high glucose and ablates sulfonylurea-stimulated insulin secretion (9; 14). Similar findings were also made in clonal β-cells (15). However, these earlier studies provided no insights as to the impact of reducing mitochondrial Ca\(^{2+}\) uptake on glucose-stimulated insulin secretion in vivo, nor how this may, in turn, impact the physiology of the living animal.

Tissue-specific manipulation of MCU activity provides an alternative and powerful means to examine the role of mitochondrial Ca\(^{2+}\) in particular tissue or cell type. In the present study we have therefore generated mice in which Mcu is deleted highly selectively in the pancreatic β-cell, and explored the impact on insulin secretion and whole body glucose homeostasis. We
show that mitochondrial Ca$^{2+}$ uptake, glucose-induced ATP increases and insulin secretion are 
substantially impaired in vitro in dissociated or islets from KO mice. Insulin release is also 
impaired in the living mouse, despite improvements in glucose tolerance.
Materials and Methods

Generation of β-cell specific MCU-KO mice

All in vivo procedures were approved by the UK Home Office according to the Animals (Scientific Procedures) Act 1986. Animals were fed ad libitum with a standard mouse chow diet (Research Diets, Inc) unless otherwise stated. For high fat/sucrose diet (HFHS) treatment, mice were placed on diet at 5-6 weeks of age for 2 weeks (58% [wt/wt] fat and sucrose content; Research Diets, Inc) prior to analysis.

C57BL/6J mice bearing Mcu (also termed Ccdc109a and C10orf42) alleles with FloxP sites flanking exons 11 and 12 were generated by GenOway (Grenoble, Fr) and bred to animals carrying Cre recombinase inserted at the Ins1 locus (Ins1Cre) (16). Use of this Cre line allowed efficient and β-cell-selective deletion of both Mcu splice variants (βMCU-KO), without recombination in the brain or confounding expression of human growth hormone. Mice bearing floxed Mcu alleles but lacking Cre recombinase were used as littermate controls (WT). Possession of Ins1Cre alleles alone exerted no effect on glycaemic phenotype (not shown). The sequences of primers used for genotyping and qRT-PCR for Mcu, Kcnj11 and Abcc8 are provided under Supplemental Tables 1 and 2.

For measurements of mRNA levels, pancreatic islets were isolated by collagenase digestion (17). Deletion of Mcu was determined using quantitative real-time PCR. RNA was extracted from islets using Trizol (Invitrogen) and reverse transcribed using a high capacity reverse transcription kit (Invitrogen) (18). Relative gene expression was determined using SYBR Green (Invitrogen), and expression of Mcu was normalised to β-actin mRNA.
Intraperitoneal glucose, insulin tolerance tests and measurement of insulin secretion in vivo

To investigate glucose tolerance, male or female mice (ages 8-24 weeks as indicated) were fasted overnight for 16 h before injection of glucose solution (20% w/v, 1g/kg body weight) intraperitoneally. Glucose was measured in tail vein blood at 0, 5, 15, 30, 60, 90 and 120 min. using an ACCU-CHECK Aviva glucometer (Roche) (19).

To ascertain insulin tolerance, mice were fasted for 5 h before human insulin (0.75 units/kg body weight, Sigma Aldrich) was injected intraperitoneally. Blood glucose was measured in tail vein blood at 0, 15, 30 and 60 min. (19).

For in vivo insulin secretion experiments, animals were fasted overnight for 16 h and glucose (20% w/v, 3 g/kg body weight) was either given intraperitoneally or oral gavage. Plasma was separated by centrifugation and insulin was measured using an ultra-sensitive mouse insulin ELISA kit (CrystalChem).

Single cell fluorescence imaging

Pancreatic islets were isolated as above, dissociated into single β-cells and plated onto glass coverslips (9; 20). Mitochondrial Ca$^{2+}$ uptake was measured via adenovirus-mediated delivery of a mitochondrially-targeted recombinant Ca$^{2+}$ probe, R-GECO (21). Cells were infected and incubated for 48 h prior to imaging in Krebs-Ringer bicarbonate buffer (140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH$_2$PO$_4$, 2 mM NaHCO$_3$ (saturated with CO$_2$), 1.5 mM CaCl$_2$, 0.5 mM MgSO$_4$, 10 mM HEPES and 3 mM D-glucose, pH7.4). To examine ATP:ADP changes in response to a rise in extracellular glucose concentration, dissociated β-cells were infected with an adenovirus bearing cDNA encoding the ATP sensor Perceval (9) and incubated for 48 h prior to fluorescence imaging. In all experiments, cells were equilibrated for at least 30 min. in Krebs-Ringer bicarbonate containing 3 mM glucose prior to the start of acquisitions.
Excitation/emission wavelengths were (nm): 490/630 and 410/630 (Fura-Red), 530/590 (R-GECO) and 470/535 (Perceval). All imaging experiments were performed using an Olympus IX71 microscope with 40x magnification objective, an F-View-II camera and an MT-20 excitation system equipped with a Hg/Xe arc lamp with image capture at 0.2 Hz excitation time (50 ms).

For experiments with tetramethylrhodamine (TMRE), β-cells were loaded with 10nM TMRE in imaging buffer (140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 24 mM NaHCO3 (saturated with CO2), 1.5 mM CaCl2, 0.5 mM MgSO4, 10 mM HEPES and 3 mM glucose) for 45 min. and re-equilibrated with 2nM TMRE for 10 min. before recordings. TMRE (2nM) was present throughout, and cells excited at 550 nm. FCCP (Carbonyl cyanide-4-phenylhydrazone, 1μM) was administrated as indicated and imaging performed using a Zeiss AxioObserver microscope using 63x 1.4NA oil objective, a Hamamatsu Flash 4 camera and an LED (light emitting diode) excitation system (excitation filter 534/20nm and emission filter 572/28nm) at 0.3 Hz (250 ms exposure). Traces represent mean normalised fluorescence intensity (F/F_min) over time, where F_min is the average fluorescence recorded at 3mM glucose.

Whole islet fluorescence imaging

Ca2+ imaging of whole islets was performed after loading with Cal-520 AM (Stratech;2 μM), or mito Pericam adenovirus (MOI 100), and perifusion in Krebs-Ringer bicarbonate buffer containing 3mM or 17mM glucose, 17mM glucose with 0.1mM diazoxide or 20mM KCl. Images were captured at 0.5Hz on a Zeiss Axiovert microscope equipped with a 10X 0.3–0.5 NA oil immersion objective, coupled to a Nipkow spinning-disk head (Yokogawa CSU-10) and illuminated at 491nm. Data were analysed using ImageJ with a purpose-designed macro (available upon request).
**In vitro insulin secretion**

Insulin secretion assays were performed on islets isolated from male mice (8-10 weeks) (24). Secreted and total insulin were quantified using a homogeneous time-resolved fluorescence (HTRF) insulin kit (Cisbio) in a PHERAstar reader (BMG Labtech, UK) following the manufacturer's guidelines. Data are presented as secreted insulin/insulin content.

**Electrophysiology**

Electrophysiological recordings were performed on single β-cells in perforated patch-clamp configuration using an EPC9 patch-clamp amplifier controlled by Pulse acquisition software (Heka Elektronik, Pfalz, Germany). β-cells were identified morphologically and by depolarisation of the membrane potential in response to 17 mM glucose. β-cells were constantly perfused at 32 °C with normal saline solution (135mM NaCl, 5mM KCl, 1mM MgCl$_2$, 1mM CaCl$_2$, 10mM HEPES). Recording electrodes had resistances of 8-10 MΩ and were filled with a solution comprised of 140mM KCl, 5mM MgCl$_2$, 3.8mM CaCl$_2$, 10mM HEPES, 10mM EGTA (pH 7.2) and 20–25 μg/ml amphotericin B (Sigma-Aldrich).

Voltage-dependent calcium channel (VDCCs) currents were recorded from dispersed mouse β-cells as previously described (22).

**β-cell mass**

Whole pancreatic optical projection tomography, to 19 µm resolution, was performed as described (23).

**Statistical Analysis**

Data are expressed as mean ± SEM except for small datasets (n<3), where data are shown as mean ± S.D. Significance was tested by Student’s two-tailed t-test, one or two-way ANOVA.
with Sidak’s or Bonferroni multiple comparison test for comparison of more than two groups, using GraphPad Prism 7 software. $p<0.05$ was considered significant.
Results

Mcu ablation from pancreatic β-cells attenuates GSIS in vitro

To ablate MCU from pancreatic β-cells, animals bearing alleles in which LoxP sites flanked exons 11 and 12 of the Mcu gene were generated (See Materials and Methods) and crossed to mice harbouring Cre recombinase inserted at the Ins1 locus (16) (Fig. 1A). This strategy ensured targeted deletion of the longer splice variant of Mcu, which predominates in islets (results not shown), whilst excluding any compensatory increase in the expression of the shorter variant. Mcu deletion was confirmed by qRT-PCR (Fig. 1B). Relative to β-Actin (Actb), expression of the Mcu transcript in KO islets was decreased by ~75% vs control islets (p<0.05; Fig. 1B). This level of reduction is consistent with near-complete elimination of Mcu mRNA from β-cells, assuming a β-:α-cell ratio of ~3:1 (24) and similar levels of Mcu expression in each cell type in WT islets (25).

We next explored the consequences for glucose-stimulated insulin secretion in isolated βMCU-KO islets. In perifusion experiments, βMCU-KO islets displayed a significant blunting in the secretory response to elevated glucose, with the attenuation in insulin release most evident at high glucose concentrations (17 mM), as determined at the first peak (p<0.05; Fig. 1C). These results were confirmed by independent experiments involving batch incubation of islets (p<0.01; Fig. 1D). In contrast, βMCU-KO islets displayed no difference vs control islets in insulin secretion stimulated by depolarisation with 20 mM KCl in either system (data not shown).
MCU deletion from pancreatic β-cells impairs glucose-stimulated mitochondrial but not
cytosolic Ca\(^{2+}\) uptake

Since MCU provides the main route for Ca\(^{2+}\) entry into mitochondria in other cell types (26),
we first determined the impact of deleting \(MCU\) on this process in pancreatic β-cells. Changes
in mitochondrial free Ca\(^{2+}\) concentration ([Ca\(^{2+}\)\(_{\text{mt}}\)] \_) were investigated by live cell fluorescence
microscopy using whole or dissociated islets expressing an adenovirus (mito Pericam), or a
genetically-encoded Ca\(^{2+}\) indicator (R-GECO), respectively (21). After pre-incubation in the
presence of low (3 mM) glucose, increases in [Ca\(^{2+}\)\(_{\text{mt}}\)] \_ were provoked in control islets or β-cells
by stimulation with high (17 mM) glucose or plasma membrane depolarisation with KCl (20
mM). A depolarising K\(^{+}\) concentration and the K\(_{\text{ATP}}\) channel opener diazoxide were then
deployed together to bypass glucose regulation of the K\(_{\text{ATP}}\) channel (Fig. 2C’, E’).

\(Mcu\) deletion attenuated glucose-stimulated increases in [Ca\(^{2+}\)\(_{\text{mt}}\)] \_ in dissociated islets (Fig. 2A-
B), as demonstrated within normalised traces and by determination of the mean area under the
curve at 17mM glucose (AUC; \(<\text{p}\>0.05). The [Ca\(^{2+}\)\(_{\text{mt}}\)] \_ increase in response to depolarisation
with KCl was largely maintained in βMCU-KO. The [Ca\(^{2+}\)\(_{\text{mt}}\)] \_ was also assessed in whole islets
using mito Pericam where a trend towards reduced mitochondrial Ca\(^{2+}\) uptake was observed
(Fig. 2C-D). To determine whether the impaired [Ca\(^{2+}\)\(_{\text{mt}}\)] \_ changes in βMCU-KO β-cells may
simply reflect altered cytosolic Ca\(^{2+}\) ([Ca\(^{2+}\)\(_{\text{cyt}}\)] \_) dynamics, the latter were also explored using
the Ca\(^{2+}\)-sensitive dye (Cal-520) in whole islets. Interestingly, [Ca\(^{2+}\)\(_{\text{cyt}}\)] \_ increases in whole
βMCU-KO islets were significantly increased in response to glucose in comparison to WT
animals (AUC; \(<\text{p}\>0.001; \text{Fig. 2E, F}).

MCU deletion from pancreatic β-cells reduces mitochondrial ATP production and
cytosolic accumulation whereas mitochondrial membrane depolarisation decreases in
response to glucose
Given the significant reduction in GSIS observed in βMCU-KO islets *in vitro* and despite improved cytosolic Ca$^{2+}$ dynamics, we next sought to determine whether an alteration in glucose metabolism might contribute to the attenuated insulin secretion. To address this, we utilised real-time fluorescence imaging of the ATP sensor, Perceval (9). A rise in the ATP:ADP ratio was prompted in control β-cells by a step increased in glucose from 3 to 17 mM (9). This change was significantly blunted in *Mcu* null β-cells (AUC; p<0.05; Fig. 3A, B). This was accompanied by a potentiation in the increase in mitochondrial membrane potential ($\Delta \psi_m$), as assessed by monitoring TMRE fluorescence in βMCU-KO mouse β-cells (AUC$_{700-720s}$; p<0.05; Fig. 3C, D).

Altered ATP production in response to high glucose is expected to affect the activity of K$_{ATP}$ channels (27). Assessed in single β-cells using perforated patch-clamp electrophysiology (9), the extent of membrane potential depolarisation in response to a step increase in extracellular glucose from 3 to 17 mM did not differ significantly between βMCU-KO and control β-cells, although there was a trend towards weaker depolarisation in KO cells (Fig. 3E, F). VDCC currents, measured by whole-cell voltage clamp (22), displayed no apparent differences in response to 17 mM glucose (Fig. 3G). Interestingly expression of the K$_{ATP}$ channel subunit *Kcnj11* was significantly elevated in βMCU-KO islets (AUC; p<0.05; Fig. 3H) any may contribute to reduced electrical activity (Fig. 3E, F).
Lowered β-cell mass in MCU-deleted mice

Analysis using optical projection tomography (OPT; Fig. 4A) revealed that pancreata from βMCU-KO mice displayed decreased numbers of islets at the extremes of the size spectrum (p<0.01) in comparison to WT mice (Fig. 4B) and a decrease in total β-cell volume (AUC; p<0.01; Fig. 4C).

Loss of MCU from pancreatic β-cells does not alter body mass or fed glycaemia but impairs GSIS in vivo

We next explored the role of β-cell MCU in the control of insulin secretion and in vivo glucose homeostasis. βMCU-KO animals displayed normal growth and weight changes from 6 to 24 weeks (Fig. S1A). However, male βMCU-KO mice showed a slight, but significant, increase (p<0.05) in weight gain from 20-24 weeks. We observed no differences in random fed blood glucose levels between βMCU-KO and control animals at all ages examined (Fig. S1B). No genotype-dependent differences in the above metabolic parameters were observed in female mice at any age (Fig. S1C, S1D; Fig. S2A-D).

Glucose tolerance was investigated in βMCU-KO and WT mice by intraperitoneal injection of 1g/kg body weight glucose (IPGTT) at 8, 12, 16 and 24 weeks of age. A small but significant improvement in glucose tolerance was observed in male βMCU-KO mice vs controls at 8 (p<0.001) or 12 (p<0.05) weeks of age (Fig. 5A, B). Older male animals displayed unaltered glucose tolerance (Fig. 5C, D) vs WT mice.

To assess GSIS in vivo, 8-10 week-old male mice were challenged with 3g/kg glucose and plasma insulin sampled at 0, 5, 15 and 30 min. (Fig. 6A, B). Although improved glucose tolerance was observed in βMCU-KO animals post 15 min. IP administration (Fig. 6A), a dramatic reduction (p<0.001) in insulin release was observed 5 min. post-glucose injection
βMCU-KO animals also displayed improved oral glucose tolerance at 15 and 30 min. post-oral gavage ([Fig. 6B](#)); $p<0.05$, increased insulin secretion at 5 min. ([Fig. 6D](#)); $p<0.05$ vs WT littermates. No differences in intraperitoneal insulin tolerance ([Fig. 6E, F](#)) or c-peptide levels (not shown) were observed between WT and KO mice.

Finally, to impose a metabolic stress, βMCU-KO mice and control littermates were maintained on a HFHS diet and subjected to the same tests as in ([Fig. 6A, B](#)). Again, no differences in glycaemia or insulin secretion were observed between phenotypes ([Fig. S3A, B](#)). No genotype-dependent differences in c-peptide secretion were apparent (not shown).
Discussion

Mitochondria are highly dynamic organelles which play an important role in maintaining normal β-cell function and secretory responses to glucose (28-30). As mitochondrial dynamics and biogenesis are impaired in the face of insulin resistance and in type 2 diabetes in these cells (8), it is conceivable that preserving the normal function of these organelles may slow the loss of normal insulin secretion and disease progression (31; 32).

Recent findings (10) have demonstrated the importance of MCU for Ca$^{2+}$ uptake into mitochondria in several mammalian cell types, and established this as the most important route for Ca$^{2+}$ accumulation into these organelles. In the present studies, efficient deletion of both MCU isoforms was achieved by targeting exons 11 and 12 of the Mcu gene using recombination with efficient and selective Ins1Cre deleter strain. This resulted in near complete elimination of a functional Mcu gene throughout the β-cell population in vivo. In agreement with previous studies using RNA silencing (9; 15), Mcu deletion attenuated GSIS and mitochondrial Ca$^{2+}$ uptake in response to high glucose in dissociated islets (9). The response to depolarisation by KCl was less markedly affected, possibly reflecting the opening of other mitochondrial Ca$^{2+}$ transporters/channels at high cytosolic [Ca$^{2+}$] levels (33). Alternative mitochondrial Ca$^{2+}$ entry pathways may involve ryanodine receptors, as observed on the inner mitochondrial membrane in neurons (34), or the rapid mode of mitochondrial Ca$^{2+}$ uptake (RAM) in the liver. The existence of these pathways has not, as yet, been demonstrated in pancreatic β-cells.

Surprisingly, quantification of [Ca$^{2+}$]c, in intact islets demonstrated larger increases in response to high glucose in KO islets (Fig.7A,B), perhaps reflecting an impact on Ca$^{2+}$ oscillation frequency, β cell-β cell communication and three-dimensional electrical communication through gap junctions (35). The sharp decrease in GSIS in vitro in the face of
higher cytosolic \( \text{[Ca}^{2+}] \) (Fig.7B) is, again, paradoxical and argues that lowered ATP:ADP, alongside impairments in amplifying processes (36), such as the \( \text{Ca}^{2+} \)-dependent intra-mitochondrial generation of putative coupling molecules such as glutamate (37), or others (2), exert a dominant, inhibitory effect on secretion in KO mice (see below).

Importantly, our observations support the view that \( \text{Ca}^{2+} \) accumulation by mitochondria stimulates ATP consumption, consistent with a reduction in glucose-stimulated ATP:ADP ratio in the KO mouse (6). Additionally, mitochondrial membrane potential was increased, particularly in glucose-stimulated conditions, in dissociated islets from KO vs WT mice. An increase in \( \Delta \psi_m \) in the face of lowered cytosolic ATP:ADP is consistent with a decrease in \( \text{F}_1/\text{F}_0 \text{ATPase} \) activity (38) (Fig.7B), an enzyme previously reported to be \( \text{Ca}^{2+} \) regulated in other tissues (8). Reduced mitochondrial \( \text{Ca}^{2+} \) extrusion via flux through the mitochondrial \( \text{Na}^+/\text{Ca}^{2+} \) exchanger NCLX (electrogenic: 3\( \text{Na}^+ \): 1\( \text{Ca}^{2+} \)) may also contribute (39). Additionally, lowered cytosolic ATP is expected to restrict \( \text{Ca}^{2+} \) pumping across the plasma membrane (\( \text{Ca}^{2+} \text{ATPase} \)), as well as into the endoplasmic reticulum (SERCA; Fig.7B). Of note, despite attenuated ATP increases and greater accumulation of cytosolic \( \text{Ca}^{2+} \), we observed only a trend towards lower glucose-stimulated plasma membrane depolarisation and no significant difference in VDCC activity between WT and KO \( \beta \)-cells. Quantification of \( \text{K}_{\text{ATP}} \) channel subunit expression revealed elevated \( Kcnj11 \) mRNA levels in \( \beta \text{MCU-KO} \) mice which, alongside lowered cytosolic ATP:ADP increases, is expected to lower membrane excitability (Fig.7B) and \( \text{Ca}^{2+} \) entry (40).

In addition to the above functional alterations, \( \beta \text{MCU-KO} \) mice displayed decreased \( \beta \)-cell mass. This may reflect either impaired proliferation or generation from progenitor cells in the absence of functional \( \text{Mcu} \), or altered cell death (20). Of note, Zhao et al., (41) have recently
reported that down-regulation of MCU enhances autophagic death in neurons due to the activation of AMP-activated protein kinase (AMPK), a known regulator of β-cell mass (42).

Extending to the in vivo setting, the current and earlier (9; 15) in vitro data demonstrating roles for MCU in the control of glucose-induced insulin secretion, we show that insulin secretion is impaired in βMCU-KO vs control mice 5 min. post to intraperitoneal injection of glucose. Surprisingly, however, insulin secretion post-oral gavage was elevated in KO mice at 5 min. perhaps suggesting that gut-derived factors such as the gastric inhibitory polypeptide and glucagon-like peptide-1 (GIP and GLP-1) are partially responsible for the enhanced glucose-stimulated insulin secretion from the β-cells (43). Future studies will be necessary to explore this possibility.

Interestingly, earlier studies inactivating MCU globally in the mouse, or in selected tissues, have consistently reported relatively minor phenotypes (44). Global MCU null mice displayed relatively unimpaired cardiac and skeletal muscle function and respiration (11) despite a near-complete ablation of Ca\(^{2+}\) accumulation by mitochondria in these cells. The present results are thus in line with these earlier findings. It is still unknown why insulin secretion is acutely impaired 5 min. post intraperitoneal glucose administration in KO mice but compensatory mechanisms are likely to emerge after that period to maintain normal cellular energy homeostasis and signalling in vivo. One intriguing possibility, which may be of particular relevance to the nutrient-responsive β-cell, is that the mitochondrial Na\(^+\)-Ca\(^{2+}\) exchanger NCLX operates in the reverse mode at low Δψ\(_{m}\), thus allowing Ca\(^{2+}\) influx (45) to provide a compensatory mechanism for the loss of MCU.

The findings here also provide evidence of a role for additional, mitochondrially-derived metabolic signals whose generation depends upon mitochondrial Ca\(^{2+}\) uptake and which serve to potentiate the actions of increased cytosolic Ca\(^{2+}\). Such molecules have been proposed to
underlie the “amplification” ($K_{\text{ATP}}$-channel independent) component of glucose-stimulated insulin secretion (36) but still remain elusive. Recent studies have focused on mitochondrial pathways of glucose metabolism, and the generation of second messengers other than ATP that such pathways might generate. Islet β-cells express both pyruvate carboxylase (PC) and pyruvate dehydrogenase (PDH) in abundance, such that, in the fed state, pyruvate flows into mitochondrial metabolic pathways in roughly equal proportions through the anaplerotic and oxidative entry points (2; 46). Impairments in pyruvate/isocitrate cycle activity, and the generation of its by-products (notably α-ketoglutarate (α-KG) and NADPH) might therefore restrict normal insulin secretion in βMCU-KO mice (Fig.7B).

**Conclusion**

To the best of our knowledge, this study provides only the second description of a conditional null $Mcu$ KO mouse and reveals a critical role for MCU-mediated mitochondrial Ca$^{2+}$ influx in the pancreatic β-cell in vitro and in vivo. The mechanisms which compensate in vivo for defective insulin secretion in βMCU-KO mice, ensuring near-normal or improved glucose homeostasis will need further exploration in the future.

Our findings suggest that changes in MCU expression or activity may contribute to defective insulin secretion in some forms of diabetes. An alteration in the ratio of the active (MCUa) form of the channel versus MCUb, a dominant-negative form of the carrier (26), might also play a part in the disease process in some settings.

**Conflict of interest**

The authors declare that they have no conflicts of interest with the contents of this article.

19
Funding

G.A.R. was supported by a Wellcome Trust Senior Investigator Award (WT098424AIA) and Investigator Award (212625/Z/18/Z), MRC Programme grants (MR/R022259/1, MR/J0003042/1, MR/L020149/1) and Experimental Challenge Grant (DIVA, MR/L02036X/1), MRC (MR/N00275X/1), Diabetes UK (BDA/11/0004210, BDA/15/0005275, BDA16/0005485) and Imperial Confidence in Concept (ICiC) grants, and a Royal Society Wolfson Research Merit Award. I.L. was supported by Diabetes UK Project Grant 16/0005485. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881 (RHAPSODY). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This work is supported by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 16.0097. RR was supported by grants from the Italian Ministries of Health (Ricerca Finalizzata.) and of Education, University and Research (FIRB), the European Union (ERC mitoCalcium, no. 294777), the National Institutes of Health (grant #1P01AG025532-01A1), the Italian Association for Cancer Research (AIRC IG18633), and Telethon-Italy (GGP16029).

Author contributions

E.H, E.G. and G.dSX performed experiments and analysed data. F.S. and M.C.C. generated and amplified Perceval and R-GECO viruses. I.L. and A.M.S. were responsible for the maintenance and genotyping of mouse colonies. T.J.P. examined RNAseq data and designed experiments. R.R. provided reagents. G.A.R. designed the study and wrote the manuscript with E.H. and E.G., with input from all authors. G.A.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Data and Resource Availability

All data generated or analyzed during this study are included in the published article (and its online supplementary files). No applicable resources were generated or analyzed during the current study.

Prior presentation

Some of this work has been presented at the following conferences: as a poster at the EASD Annual conference, Lisbon, Portugal, September 2017, with an accompanying abstract in Haythorne, E.A., Martinez-Sanchez, A., Rizzuto, R., and Rutter, G.A. The mitochondrial uniporter (MCUa) is required for glucose-stimulated mitochondrial Ca\(^{2+}\) uptake and insulin secretion in mouse pancreatic beta cells, *Diabetologia*, 60, Suppl1, S1-S608. 431 (2017): as a poster at the Diabetes UK Annual Professional Conference, London, U.K., March 2018, with the accompanying abstract: Rutter, G.A. Haythorne, E.A., Georgiadou, E., Da Silva Xavier, G., Pullen, T.J., Rizzuto, R., Martinez-Sanchez, A., McGinty, J.A. and French, P.M. Pancreatic beta cell-selective deletion of the mitochondrial Ca\(^{2+}\) uniporter MCU impairs glucose stimulated insulin secretion in vitro but not in vivo. *Diabetic Med* 35:42 (2018). Data were also included in an oral presentation at a conference entitled “Mitochondrial Form and Function” at University College London, U.K., September 2017.
415 **Abbreviations**

416 $[\text{Ca}^{2+}]_{\text{cyt}}$: Cytoplasmic Ca$^{2+}$ concentration

417 $[\text{Ca}^{2+}]_{\text{mt}}$: Mitochondrial Ca$^{2+}$ concentration

418 ADP: Adenosine diphosphate

419 AMPK: Adenosine monophosphate-activated protein kinase

420 ANT: adenine nucleotide transferase

421 ATP: Adenosine triphosphate

422 AUC: Area under curve

423 FCCP: Carbonyl cyanide-4-phenylhydrazone

424 GIP: Gastric inhibitory polypeptide

425 GLP-1: Glucagon-like peptide-1

426 GSIS: Glucose-stimulated insulin secretion

427 HTRF: homogeneous time-resolved fluorescence-based assay

428 IPGTT: Intraperitoneal glucose tolerance test

429 KATP: ATP-sensitive K$^+$ (K$_{\text{ATP}}$) channels

430 KCl: Potassium chloride

431 KO : Knockout

432 MCU: Mitochondrial Ca$^{2+}$ uniporter

433 NCLX: Na$^+$-Ca$^{2+}$ exchanger

434 OGTT :Oral gavage tolerance test

435 PC: Pyruvate carboxylase

436 PDH: Pyruvate dehydrogenase

437 RAM: Rapid mode of mitochondrial Ca$^{2+}$ uptake

438 SERCA: Sarco/endoplasmic reticulum Ca$^{2+}$-ATPase

439 T2D: Type 2 diabetes

440 TCA: tricarboxylic acid

441 TMRE: Tetramethylrhodamine ethyl ester
VDCCS: Voltage-dependent Ca^{2+} channels

WT: Wild type

βMCU-KO: Mitochondrial Ca^{2+} uniporter null animal in the beta cell

α-KG: α-ketoglutarate

Δψ_{m}: Mitochondrial membrane potential
1. Kahn SE, Zraika S, Utzschneider KM, Hull RL: The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009;52:1003-1012

2. Rutter GA, Pullen TJ, Hodson DJ, Martinez-Sanchez A: Pancreatic beta-cell identity, glucose sensing and the control of insulin secretion. Biochem J 2015;466:203-218

3. Rutter GA, Theler JM, Murgia M, Wollheim CB, Pozzan T, Rizzuto R: Stimulated Ca2+ influx raises mitochondrial free Ca2+ to supramicromolar levels in a pancreatic beta-cell line. Possible role in glucose and agonist-induced insulin secretion. Journal of Biological Chemistry 1993;268:22385-22390

4. Kennedy ED, Rizzuto R, Theler JM, Pralong WF, Bastianutto C, Pozzan T, Wollheim CB: Glucose-stimulated insulin secretion correlates with changes in mitochondrial and cytosolic Ca2+ in aequorin-expressing INS-1 cells. The Journal of Clinical Investigation 1996;98:2524-2538

5. Denton RM, McCormack JG: On the role of the calcium transport cycle in heart and other mammalian mitochondria. FEBS Lett 1980;119:1-8

6. Drews G, Bauer C, Edalat A, Dufer M, Krippeit-Drews P: Evidence against a Ca(2+)-induced potentiation of dehydrogenase activity in pancreatic beta-cells. Pflugers Arch 2015;467:2389-2397

7. Wiederkehr A, Wollheim CB: Mitochondrial signals drive insulin secretion in the pancreatic beta-cell. Mol Cell Endocrinol 2012;353:128-137

8. Anello M, Lupi R, Spampinato D, Piro S, Masini M, Boggi U, Del Prato S, Rabuazzo AM, Purrello F, Marchetti P: Functional and morphological alterations of mitochondria in pancreatic beta-cells from type 2 diabetic patients. Diabetologia 2005;48:282-289

9. Tarasov AI, Semplici F, Ravier MA, Bellomo EA, Pullen TJ, Gilon P, Sekler I, Rizzuto R, Rutter GA: The mitochondrial Ca2+ uniporter MCU is essential for glucose-induced ATP increases in pancreatic beta-cells. PLoS One 2012;7:e39722

10. De Stefani D, Patron M, Rizzuto R: Structure and function of the mitochondrial calcium uniporter complex. Biochim Biophys Acta 2015;1853:2006-2011

11. Pan X, Liu J, Nguyen T, Liu C, Sun J, Teng Y, Fergusson MM, Rovira, II, Allen M, Springer DA, Aponte AM, Gucek M, Balaban RS, Murphy E, Finkel T: The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. Nat Cell Biol 2013;15:1464-1472
12. Quan X, Nguyen TT, Choi SK, Xu S, Das R, Cha SK, Kim N, Han J, Wiederkehr A, Wollheim CB, Park KS: Essential role of mitochondrial Ca2+ uniporter in the generation of mitochondrial pH gradient and metabolism-secretion coupling in insulin-releasing cells. J Biol Chem 2015;290:4086-4096

13. Hou T, Zhang X, Xu J, Jian C, Huang Z, Ye T, Hu K, Zheng M, Gao F, Wang X, Cheng H: Synergistic triggering of superoxide flashes by mitochondrial Ca2+ uniport and basal reactive oxygen species elevation. J Biol Chem 2013;288:4602-4612

14. Tarasov AI, Semplici F, Li D, Rizzuto R, Ravier MA, Gilon P, Rutter GA: Frequency-dependent mitochondrial Ca(2+) accumulation regulates ATP synthesis in pancreatic β cells. Pflugers Archiv: European journal of physiology 2013;465:543-554

15. Alam MR, Groschner LN, Parichatikanond W, Kuo L, Bondarenko AI, Rost R, Waldeck-Weiermair M, Malli R, Graier WF: Mitochondrial Ca2+ uptake 1 (MICU1) and mitochondrial Ca2+ uniporter (MCU) contribute to metabolism-secretion coupling in clonal pancreatic β-cells. Journal of Biological Chemistry 2012;287:42453

16. Thorens B, Tarussio D, Maestro MA, Rovira M, Heikkila E, Ferrer J: Ins1(Cre) knock-in mice for beta cell-specific gene recombination. Diabetologia 2015;58:558-565

17. Ravier MA, Rutter GA: Isolation and culture of mouse pancreatic islets for ex vivo imaging studies with trappable or recombinant fluorescent probes. Methods Mol Biol 2010;633:171-184

18. Martinez-Sanchez A, Nguyen-Tu MS, Rutter GA: DICER Inactivation Identifies Pancreatic beta-Cell "Disallowed" Genes Targeted by MicroRNAs. Mol Endocrinol 2015;29:1067-1079

19. Mehta ZB, Fine N, Pullen TJ, Cane MC, Hu M, Chabosseau P, Meur G, Velayos-Baeza A, Monaco AP, Marselli L, Marchetti P, Rutter GA: Changes in the expression of the type 2 diabetes-associated gene VPS13C in the beta-cell are associated with glucose intolerance in humans and mice. Am J Physiol Endocrinol Metab 2016;311:E488-507

20. Hodson DJ, Mitchell RK, Bellomo EA, Sun G, Vinet L, Meda P, Li D, Li WH, Bugliani M, Marchetti P, Bosco D, Piemonti L, Johnson P, Hughes SJ, Rutter GA: Lipotoxicity disrupts incretin-regulated human beta cell connectivity. The Journal of clinical investigation 2013;123:4182-4194

21. Wu J, Prole DL, Shen Y, Lin Z, Gnanasekaran A, Liu Y, Chen L, Zhou H, Chen SR, Usachev YM, Taylor CW, Campbell RE: Red fluorescent genetically encoded Ca2+ indicators for use in mitochondria and endoplasmic reticulum. Biochem J 2014;464:13-22
22. Zhu L, Almaca J, Dadi PK, Hong H, Sakamoto W, Rossi M, Lee RJ, Vierra NC, Lu H, Cui Y, McMillin SM, Perry NA, Gurevich VV, Lee A, Kuo B, Leapman RD, Matschinsky FM, Doliba NM, Urs NM, Caron MG, Jacobson DA, Caicedo A, Wess J: beta-arrestin-2 is an essential regulator of pancreatic beta-cell function under physiological and pathophysiological conditions. Nat Commun 2017;8:14295

23. Sun G, Tarasov AI, McGinty J, McDonald A, da Silva Xavier G, Gorman T, Marley A, French PM, Parker H, Gribble F, Reimann F, Prendiville O, Carzaniga R, Viollet B, Leclerc I, Rutter GA: Ablation of AMP-activated protein kinase alpha1 and alpha2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo. Diabetologia 2010;53:924-936

24. Elayat AA, el-Naggar MM, Tahir M: An immunocytochemical and morphometric study of the rat pancreatic islets. Journal of anatomy 1995;186 ( Pt 3):629-637

25. Benner C, van der Meulen T, Caceres E, Tigyi K, Donaldson CJ, Huising MO: The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression. BMC Genomics 2014;15:260

26. Mammucari C, Raffaello A, Vecellio Reane D, Rizzuto R: Molecular structure and pathophysiological roles of the Mitochondrial Calcium Uniporter. Biochim Biophys Acta 2016;1863:2457-2464

27. Ashcroft FM, Rorsman P: K(ATP) channels and islet hormone secretion: new insights and controversies. Nat Rev Endocrinol 2013;9:660-669

28. Tarasov AI, Griffiths EJ, Rutter GA: Regulation of ATP production by mitochondrial Ca(2+). Cell calcium 2012;52:28-35

29. Wiederkehr A, Szanda G, Akhmedov D, Mataki C, Heizmann CW, Schoonjans K, Pozzan T, Spat A, Wollheim CB: Mitochondrial matrix calcium is an activating signal for hormone secretion. Cell Metab 2011;13:601-611

30. Civelek VN, Deeney JT, Shalosky NJ, Tornheim K, Hansford RG, Prentki M, Corkey BE: Regulation of pancreatic beta-cell mitochondrial metabolism: influence of Ca2+, substrate and ADP. Biochem J 1996;318 ( Pt 2):615-621

31. Mulder H, Ling C: Mitochondrial dysfunction in pancreatic beta-cells in Type 2 diabetes. Mol Cell Endocrinol 2009;297:34-40

32. Ma ZA, Zhao Z, Turk J: Mitochondrial dysfunction and beta-cell failure in type 2 diabetes mellitus. Exp Diabetes Res 2012;2012:703538
33. Bondarenko AI, Jean-Quartier C, Malli R, Graier WF: Characterization of distinct single-channel properties of Ca²⁺ inward currents in mitochondria. Pflugers Archiv : European journal of physiology 2013;465:997-1010
34. Jakob R, Beutner G, Sharma VK, Duan Y, Gross RA, Hurst S, Jhun BS, J OU, Sheu SS: Molecular and functional identification of a mitochondrial ryanodine receptor in neurons. Neurosci Lett 2014;575:7-12
35. Rutter GA, Hodson DJ: Beta cell connectivity in pancreatic islets: a type 2 diabetes target? Cell Mol Life Sci 2015;72:453-467
36. Henquin JC: Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000;49:1751-1760
37. Maechler P, Wollheim CB: Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. Nature 1999;402:685-689
38. Balaban RS: The role of Ca(2+) signaling in the coordination of mitochondrial ATP production with cardiac work. Biochimica et biophysica acta 2009;1787:1334-1341
39. Palty R, Silverman WF, Hershfinkel M, Caporale T, Sensi SL, Parnis J, Nolte C, Fishman D, Shoshan-Barmatz V, Herrmann S, Khananshvili D, Sekler I: NCLX is an essential component of mitochondrial Na+/Ca2+ exchange. Proc Natl Acad Sci U S A 2010;107:436-441
40. Fridlyand LE, Jacobson DA, Philipson LH: Ion channels and regulation of insulin secretion in human beta-cells: a computational systems analysis. Islets 2013;5:1-15
41. Zhao M, Chen J, Mao K, She H, Ren Y, Gui C, Wu X, Zou F, Li W: Mitochondrial calcium dysfunction contributes to autophagic cell death induced by MPP(+) via AMPK pathway. Biochem Biophys Res Commun 2019;509:390-394
42. Kefas BA, Heimberg H, Vaulont S, Meisse D, Hue L, Pipeleers D, Van de Casteele M: AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase. Diabetologia 2003;46:250-254
43. Salehi M, Aulinger B, D'Alessio DA: Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. Diabetes 2012;61:2728-2733
44. Harrington JL, Murphy E: The mitochondrial calcium uniporter: mice can live and die without it. J Mol Cell Cardiol 2015;78:46-53
45. Samanta K, Mirams GR, Parekh AB: Sequential forward and reverse transport of the Na(+) Ca(2+) exchanger generates Ca(2+) oscillations within mitochondria. Nat Commun 2018;9:156
46. Jensen MV, Joseph JW, Ronnebaum SM, Burgess SC, Sherry AD, Newgard CB: Metabolic cycling in control of glucose-stimulated insulin secretion. American journal of physiology Endocrinology and metabolism 2008;295:E1287-E1297
Figure Legends

Figure 1. Isolated islets from βMCU-KO mice display attenuated glucose-stimulated insulin secretion in vitro.

(A) Gene deletion was achieved by breeding mice carrying Mcu alleles with FloxP sites flanking exons 11 and 12 with mice bearing Cre recombinase inserted at the Ins1 locus. (B) qRT-PCR quantification of Mcu expression (*p<0.05; n=3 mice per genotype). Values represent mean ± SD. (C) Insulin secretion from islets isolated from βMCU-WT and KO mice during perifusion and (D) serial incubations of islets in batches at 3 mM (3G) or 17 mM glucose (17G). A significant decrease in insulin secretion was observed in islets isolated from KO mice during the first peak (A; 4-8 min., p<0.05, n=4-5 mice per genotype; unpaired two-tailed Student’s t-test). In (D), a significant decrease was observed between genotypes in secretion stimulated by 17 mM glucose (p<0.01; two-way ANOVA test and Sidak’s multiple comparisons test) compared to WT mice (n=6 WT, n=7 KO animals). Blue circles, βMCU-WT, red squares, βMCU-KO mice.

Figure 2. MCU deletion from pancreatic β-cells diminishes in vitro mitochondrial Ca2+ uptake in dissociated islets but not cytoplasmic [Ca2+] in whole islets.

(A) Genetically-encoded recombinant Ca2+ probe, R-GECO, was used to assess mitochondrial Ca2+ dynamics in response to 17 mM glucose and 20 mM KCl in dissociated β-cells. (B) AUC corresponding to the data shown in (A): *p<0.05; n=5 trials, 3 mice per genotype; data points correspond to individual trials; 8-15 min for stimulation with 17 mM glucose. (C’) Each snapshot of isolated WT (upper panel) and KO (lower panel) islets was taken during the time points shown with an arrow. See also supplemental movies Pericam WT and Pericam KO. (C) Mitochondrial Ca2+ changes in response to 17 mM glucose (with or without diazoxide) and 20
mM KCl were assessed following mito Pericam infection. Traces represent mean normalised fluorescence intensity (F/F_{min}) over time. Scale bar= 50μm. (D) AUC corresponding to the data shown in (C): n=5-6 trials, 3 mice per genotype; data points correspond to individual trials; no significant differences detected. (E’) Each snapshot of isolated WT (upper panel) and KO (lower panel) islets was taken during the time points shown with an arrow. See also supplemental movies Cal-520 WT and Cal-520 KO. (E) Cytoplasmic Ca^{2+} changes in response to 17 mM glucose (with or without diazoxide) and 20 mM KCl were assessed following Cal-520 uptake. Traces represent mean normalised fluorescence intensity (F/F_{min}) over time. Scale bar= 50μm. (F) AUC corresponding to the data shown in (E): ***p<0.001; n=5 trials, 3 mice per genotype; data points correspond to individual trials. Islets were isolated from 8-10 week old male mice maintained on standard chow diet. Values represent mean ± SEM. AU, arbitrary unit; AUC, area under the curve. Statistical analyses were performed using two-way ANOVA tests and Sidak’s correction for multiple comparisons.

Figure 3. MCU ablation from pancreatic β-cells diminishes ATP production and mitochondrial membrane depolarisation in response to high glucose.

(A) Changes in the ATP:ADP ratio in response to 17 mM glucose was examined in dissociated β-cells using the ATP sensor Perceval. (B) AUC values corresponding to (A) (p<0.05, n=6-7 trials, 3 mice per genotype; unpaired two-tailed Student’s t-test). (C) Cells were loaded with TMRE to measure changes in ΔΨ_m, and perifused with 3 mM, 17 mM glucose or 1μM FCCP as indicated. Traces represent normalised fluorescence intensity (F/F_{min}) over time. (D) AUC were determined from the data shown in (C): AUC_{700-720s} peak at 17mM glucose (p<0.05) and presented as mean of the values ± SEM. Data points are from n=3 mice per genotype (two trials per mouse). (E) Representative current-clamp recordings of individual β-cells from WT (upper trace) and βMCU-KO mice (lower trace) displaying the membrane potential response.
from 3 to 17 mM glucose. (F) Mean membrane potential responses \( n=5-7 \) trials, 3 mice per genotype; two-way ANOVA test and Sidak’s multiple comparisons test. (G) Activation of β-cell VDCCs in response to 17mM glucose and indicated voltage steps \( n=23-24 \) islets, 3 mice per genotype). (H) qRT-PCR quantification of \( Kcnj11 \) and \( Abb8 \) expression (*\( p<0.05; n=4-6 \) mice per genotype; unpaired two-tailed Student’s t-test and Mann Whitney correction). Islets were isolated from 8-10 week old male mice maintained on standard chow diet. Values represent mean ± SEM. AU, arbitrary unit; AUC, area under the curve.

**Figure 4. Effect of \( Mcu \) deletion on β-cell mass.**

(A) Optical projection tomography shows images of representative pancreata stained with insulin (pseudo-colour, red) to indicate islets of different sizes. Scale bar=500 μm. (B) Quantification of the number of islets indicates a significant \( p<0.01 \) decrease in smaller islets in βMCU-KO mice \( n=6 \) animals per genotype). (C) Changes in overall β-cell mass (Area under the curve, AUC; \( p<0.01 \); unpaired two-tailed Student’s t-test and Mann Whitney correction, \( n=6 \) animals per genotype). Values represent mean ± SEM.

**Figure 5. Male βMCU-KO mice display slightly improved glucose tolerance.**

Glucose tolerance was measured in male MCU-KO and littermate control (WT) mice by intraperitoneal injection of glucose (1g/kg body weight) at (A) 8, (B) 12, (C) 16 and (D) 24 weeks of age. The AUC is shown to the right of each graph \( p<0.05 \) or \( p<0.001, n=8-14 \) mice per genotype).
**Figure 6.** $\beta$MCU-KO mice display enhanced glucose tolerance following intraperitoneal or oral gavage glucose administration.

(A) Glycaemia and (B) glucose (3 g/kg body weight)-induced insulin secretion were assessed in $\beta$MCU-KO and WT mice (p<0.05 or p<0.001; 8-10 weeks old, $n=6$-9 mice per genotype). (C) Plasma glucose and (D) insulin, during the oral glucose tolerance test in $\beta$MCU-KO and WT mice (p<0.05; $n=7$-9 per genotype). (E) Challenging 8-10 week-old male mice with a 0.75 U/kg body weight insulin injection showed normal insulin sensitivity. (F) The AUC is also shown ($n=5$ mice per genotype). All mice were maintained on a standard chow diet. Values represent mean ± SEM. AU, arbitrary unit; AUC, area under the curve.

**Figure 7.** Putative involvement of MCU in coordinating the response of $\beta$-cells to nutrient supply, and impact of MCU deletion on GSIS.

(A) Glucose is taken up by $\beta$-cells and catabolised glycolytically. The formed pyruvate is metabolised by mitochondria through the citrate (TCA) cycle, leading to an increased mitochondrial proton motive force (hyperpolarised $\Delta \psi_m$) and accelerated ATP synthesis. By entering mitochondria via the MCU, Ca$^{2+}$ potentiates oxidative metabolism to counter-balance ATP consumption. Ca$^{2+}$ exits mitochondria via NCLX. Consequently, the cytoplasmic ATP:ADP ratio rises, which causes further closure of ATP-sensitive K$^+$ channels, depolarisation of the plasma membrane potential ($\Delta \psi_c$), opening of VDCCs, and influx of Ca$^{2+}$. Elevated [Ca$^{2+}$]$_{cyt}$ triggers a number of ATP-dependent processes including insulin secretion and Ca$^{2+}$ removal into the ER (sarco(endo)plasmic reticulum Ca$^{2+}$ ATPase; SERCA) and extracellular medium (plasma membrane Ca$^{2+}$ ATPase, PMCA). Mitochondrial metabolism is also activated by amino acids such as glutamate, citrate/malate which appear to be necessary for appropriate generation of regulatory, “amplifying” signals for insulin secretion. (B) Following MCU deletion, [Ca$^{2+}$]$_{mito}$ is reduced leading to a more highly...
polarised $\Delta \psi_{\text{m}}$, weaker oxidative or amino acid metabolism and ATP synthesis, perhaps due to a decrease in mitochondrial $F_1F_0$ATPase and/or adenine nucleotide transferase (ANT) activity. This is expected to result in less closure of ATP-sensitive K$^+$ channels ($K_{\text{ATP}}$, further potentiated by increased expression of the SUR1 subunit, weaker plasma membrane depolarisation and Ca$^{2+}$ influx. Importantly, lowered ATP supply to the cytosol is expected to restrict Ca$^{2+}$ pumping across the plasma membrane, as well as into the ER. Despite reporting elevated $[\text{Ca}^{2+}]_{\text{cyt}}$ in βMCU-KO mice, insulin secretion in vitro was impaired possibly due to lower Ca$^{2+}$ dependent intra-mitochondrial generation of putative coupling molecules such as glutamate, citrate/malate.
Fig. 1
Fig. 2

**A**

![Graph showing time (sec) vs. [Ca\(^{2+}\)]\(_{cyt}\) (F/F\(_{min}\))](image)

**B**

![Bar graph showing AUC (AU) for 17 mM Glucose and 20 mM KCl](image)

**C**

![Images of fluorescence microscopy](image)

**C'**

![Images of fluorescence microscopy](image)

**D**

![Graph showing time (sec) vs. [Ca\(^{2+}\)]\(_{cyt}\) (F/F\(_{min}\))](image)

**E**

![Graph showing time (sec) vs. [Ca\(^{2+}\)]\(_{cyt}\) (F/F\(_{min}\))](image)

**E'**

![Images of fluorescence microscopy](image)

**F**

![Graph showing time (sec) vs. [Ca\(^{2+}\)]\(_{cyt}\) (F/F\(_{min}\))](image)
Fig. 3

A. 

\[
\text{[ATP/ADP]}_{\text{cyt}} \times \left( \frac{F}{F_{\text{min}}} \right)
\]

B. 

\[
\text{[ATP/ADP]}_{\text{AUC}} \times \left( \frac{F}{F_{\text{min}}} \right)
\]

C. 

\[
\Delta \nu_{m} \times \left( \frac{F}{F_{\text{min}}} \right)
\]

D. 

\[
\Delta \nu_{m} \times \text{AUC}_{\text{max}} \times \left( \frac{F}{F_{\text{min}}} \right)
\]

E. 

\[
\text{Membrane Potential (mV)}
\]

F. 

\[
\text{Max current density (pA/pF)}
\]

G. 

\[
\text{mRNA expression (relative to \( \beta\)-actin)}
\]

H. 

\[
\text{SUR1 (ABCC8), Kir6.2 (KCNJ11)}
\]
Fig. 4

A

B

C

** A U C  (A U )

5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
2 5 0 0 0
3 0 0 0 0
3 5 0 0 0
4 0 0 0 0
4 5 0 0 0
5 0 0 0 0
5 5 0 0 0
0
1 0 0
2 0 0
3 0 0
4 0 0

S i z e  (  m 3 )

N u m b e r o f is le ts

M C U  W T
M C U  K O
8 0 0 0 0
1 0 0 0 0
1 2 0 0 0 0
1 4 0 0 0 0
1 6 0 0 0 0
1 8 0 0 0 0

1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
2 5 0 0 0
3 0 0 0 0
3 5 0 0 0
4 0 0 0 0
4 5 0 0 0
5 0 0 0 0
5 5 0 0 0
0
1 0 0 0 0 0
2 0 0 0 0 0
3 0 0 0 0 0
4 0 0 0 0 0

S i z e  ( m 3 )
N u m b e r o f is le ts

M C U  W T
M C U  K O

* *
Fig. 5

A

B

C

D

Blood glucose (mmol/l)

Time (min)

MCU WT

MCU KO

AUC (AU)
Fig. 6
